In the OCEANIC-AF trial, asundexian was found to be inferior to apixaban for stroke prevention in patients with a high risk ...

Pharmacies are being forced into charging for the delivery of prescriptions as the sector faces “growing financial pressures” ...

NICE has recommended belzutifan for some adults with Von Hippel-Lindau disease, in final draft guidance, which could benefit up to 100 people. Looking back over the journey from our humble beginnings ...

In the ARTESiA trial (Apixaban for the Reduction of Thromboembolism in Patients With Device-Detected Subclinical Atrial Fibrillation), apixaban, compared with aspirin, reduced stroke or systemic ...

Apixaban and aspirin showed similar protection against major ischemic and hemorrhagic events in patients with cancer history and cryptogenic stroke. Among patients with recent cryptogenic stroke ...

Asundexian 50 mg daily was inferior to apixaban for stroke and systemic embolism prevention in high-risk patients with atrial ...

Asundexian 50 mg daily was inferior to apixaban for stroke and systemic embolism prevention in high-risk patients with atrial fibrillation (AF), according to late-breaking research presented in a ...

In both trials, patients were randomized either to anticoagulation (edoxaban in NOAH—AFNET 6 and apixaban in ARTESiA) or no anticoagulation in order to compare efficacy and safety outcomes in ...

The factor XIa inhibitor, asundexian, was compared with apixaban to assess stroke and systemic embolism prevention and bleeding rates in high-risk patients with atrial fibrillation (AF). Asundexian ...

The primary efficacy objective was to determine whether asundexian is at least noninferior to apixaban for the prevention of stroke or systemic embolism. The primary safety objective was to ...

London, United Kingdom – 1 September 2024: Asundexian 50 mg daily was inferior to apixaban for stroke and systemic embolism prevention in high-risk patients with atrial fibrillation (AF ...